Artelo Ev To Operating Cash Flow vs Roe Analysis

ARTL Stock

USD 1.05 0.08 8.25%

Artelo Biosciences financial indicator trend analysis is way more than just evaluating Artelo Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Artelo Biosciences is a good investment. Please check the relationship between Artelo Biosciences Ev To Operating Cash Flow and its Roe accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

Ev To Operating Cash Flow vs Roe

Ev To Operating Cash Flow vs Roe Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Artelo Biosciences Ev To Operating Cash Flow account and Roe. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Artelo Biosciences' Ev To Operating Cash Flow and Roe is 0.14. Overlapping area represents the amount of variation of Ev To Operating Cash Flow that can explain the historical movement of Roe in the same time period over historical financial statements of Artelo Biosciences, assuming nothing else is changed. The correlation between historical values of Artelo Biosciences' Ev To Operating Cash Flow and Roe is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Operating Cash Flow of Artelo Biosciences are associated (or correlated) with its Roe. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Roe has no effect on the direction of Ev To Operating Cash Flow i.e., Artelo Biosciences' Ev To Operating Cash Flow and Roe go up and down completely randomly.

Correlation Coefficient

0.14

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ev To Operating Cash Flow

A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.

Roe

Most indicators from Artelo Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Artelo Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.The value of Selling General Administrative is expected to slide to about 2.3 M. The value of Issuance Of Capital Stock is estimated to slide to about 538.6 K

Artelo Biosciences fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Total Current Liabilities	Accounts Payable	Capital Surpluse	Non Current Liabilities Total	Net Invested Capital	Net Working Capital	Property Plant And Equipment Net	Property Plant And Equipment Gross	Capital Stock	Short Long Term Debt Total
Total Assets		1.0	0.95	-0.97	-0.9	0.89	0.93	-0.43	0.9	0.93	0.85	1.0	-0.04	-0.85	0.84	0.85	0.87	-0.09	0.94	0.94	0.8	0.63	-0.48	-0.81
Total Stockholder Equity	1.0		0.94	-0.96	-0.89	0.89	0.92	-0.43	0.89	0.92	0.83	1.0	-0.02	-0.85	0.82	0.83	0.85	-0.11	0.94	0.94	0.82	0.64	-0.46	-0.8
Net Tangible Assets	0.95	0.94		-0.96	-0.96	0.79	0.97	-0.4	0.94	0.97	0.87	0.94	0.03	-0.85	0.86	0.9	0.87	-0.18	0.94	1.0	0.78	0.71	-0.42	-0.84
Net Debt	-0.97	-0.96	-0.96		0.88	-0.92	-0.91	0.46	-0.85	-0.9	-0.89	-0.95	-0.05	0.77	-0.88	-0.84	-0.93	0.01	-0.96	-0.95	-0.8	-0.7	0.44	0.74
Retained Earnings	-0.9	-0.89	-0.96	0.88		-0.64	-0.99	0.34	-0.99	-1.0	-0.89	-0.9	0.17	0.91	-0.88	-0.96	-0.84	0.14	-0.87	-0.95	-0.61	-0.51	0.59	0.94
Cash	0.89	0.89	0.79	-0.92	-0.64		0.69	-0.45	0.61	0.68	0.71	0.87	0.21	-0.61	0.69	0.61	0.82	0.09	0.88	0.78	0.85	0.72	-0.26	-0.48
Cash And Short Term Investments	0.93	0.92	0.97	-0.91	-0.99	0.69		-0.36	0.99	1.0	0.89	0.93	-0.16	-0.87	0.89	0.94	0.83	-0.2	0.88	0.97	0.66	0.54	-0.56	-0.94
Common Stock Total Equity	-0.43	-0.43	-0.4	0.46	0.34	-0.45	-0.36		-0.31	-0.36	-0.3	-0.39	0.36	0.28	-0.3	-0.19	-0.45	0.27	-0.5	-0.43	-0.29	-0.27	0.32	0.27
Common Stock Shares Outstanding	0.9	0.89	0.94	-0.85	-0.99	0.61	0.99	-0.31		0.99	0.84	0.91	-0.19	-0.89	0.84	0.93	0.77	-0.25	0.84	0.94	0.62	0.49	-0.56	-0.96
Other Stockholder Equity	0.93	0.92	0.97	-0.9	-1.0	0.68	1.0	-0.36	0.99		0.89	0.92	-0.16	-0.9	0.89	0.95	0.85	-0.15	0.88	0.97	0.65	0.53	-0.57	-0.93
Total Liab	0.85	0.83	0.87	-0.89	-0.89	0.71	0.89	-0.3	0.84	0.89		0.83	-0.18	-0.68	1.0	0.94	0.93	0.21	0.81	0.86	0.5	0.41	-0.69	-0.79
Total Current Assets	1.0	1.0	0.94	-0.95	-0.9	0.87	0.93	-0.39	0.91	0.92	0.83		-0.04	-0.85	0.81	0.84	0.82	-0.14	0.92	0.94	0.81	0.62	-0.46	-0.83
Common Stock	-0.04	-0.02	0.03	-0.05	0.17	0.21	-0.16	0.36	-0.19	-0.16	-0.18	-0.04		0.05	-0.21	-0.15	-0.05	0.12	0.09	0.02	0.5	0.67	0.8	0.39
Other Current Liab	-0.85	-0.85	-0.85	0.77	0.91	-0.61	-0.87	0.28	-0.89	-0.9	-0.68	-0.85	0.05		-0.67	-0.84	-0.73	0.15	-0.8	-0.85	-0.68	-0.54	0.42	0.83
Total Current Liabilities	0.84	0.82	0.86	-0.88	-0.88	0.69	0.89	-0.3	0.84	0.89	1.0	0.81	-0.21	-0.67		0.94	0.92	0.21	0.8	0.84	0.47	0.38	-0.71	-0.8
Accounts Payable	0.85	0.83	0.9	-0.84	-0.96	0.61	0.94	-0.19	0.93	0.95	0.94	0.84	-0.15	-0.84	0.94		0.87	0.11	0.8	0.89	0.52	0.43	-0.63	-0.88
Capital Surpluse	0.87	0.85	0.87	-0.93	-0.84	0.82	0.83	-0.45	0.77	0.85	0.93	0.82	-0.05	-0.73	0.92	0.87		0.26	0.87	0.86	0.61	0.55	-0.58	-0.66
Non Current Liabilities Total	-0.09	-0.11	-0.18	0.01	0.14	0.09	-0.2	0.27	-0.25	-0.15	0.21	-0.14	0.12	0.15	0.21	0.11	0.26		-0.1	-0.21	-0.2	-0.16	-0.19	0.27
Net Invested Capital	0.94	0.94	0.94	-0.96	-0.87	0.88	0.88	-0.5	0.84	0.88	0.81	0.92	0.09	-0.8	0.8	0.8	0.87	-0.1		0.94	0.8	0.73	-0.36	-0.74
Net Working Capital	0.94	0.94	1.0	-0.95	-0.95	0.78	0.97	-0.43	0.94	0.97	0.86	0.94	0.02	-0.85	0.84	0.89	0.86	-0.21	0.94		0.78	0.71	-0.4	-0.84
Property Plant And Equipment Net	0.8	0.82	0.78	-0.8	-0.61	0.85	0.66	-0.29	0.62	0.65	0.5	0.81	0.5	-0.68	0.47	0.52	0.61	-0.2	0.8	0.78		0.93	0.13	-0.43
Property Plant And Equipment Gross	0.63	0.64	0.71	-0.7	-0.51	0.72	0.54	-0.27	0.49	0.53	0.41	0.62	0.67	-0.54	0.38	0.43	0.55	-0.16	0.73	0.71	0.93		0.31	-0.27
Capital Stock	-0.48	-0.46	-0.42	0.44	0.59	-0.26	-0.56	0.32	-0.56	-0.57	-0.69	-0.46	0.8	0.42	-0.71	-0.63	-0.58	-0.19	-0.36	-0.4	0.13	0.31		0.68
Short Long Term Debt Total	-0.81	-0.8	-0.84	0.74	0.94	-0.48	-0.94	0.27	-0.96	-0.93	-0.79	-0.83	0.39	0.83	-0.8	-0.88	-0.66	0.27	-0.74	-0.84	-0.43	-0.27	0.68

Click cells to compare fundamentals

Artelo Biosciences Account Relationship Matchups

Artelo Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.5M	4.4M	12.6M	20.4M	13.0M	13.7M
Total Stockholder Equity	5.5M	3.9M	12.0M	19.4M	11.8M	12.3M
Net Tangible Assets	(135.0K)	3.4M	1.8M	10.0M	11.5M	12.1M
Net Debt	(4.4M)	(2.1M)	(6.5M)	(6.8M)	(6.1M)	(5.8M)
Retained Earnings	(4.8M)	(9.5M)	(16.9M)	(31.0M)	(40.3M)	(38.3M)
Cash	4.4M	2.1M	6.6M	6.9M	2.8M	2.6M
Cash And Short Term Investments	4.4M	2.1M	10.1M	17.5M	20.2M	21.2M
Common Stock Total Equity	11.3K	14.0K	3.4K	5.0K	4.5K	6.3K
Common Stock Shares Outstanding	144.8K	247.2K	1.2M	2.8M	3.2M	3.3M
Liabilities And Stockholders Equity	6.5M	4.4M	12.6M	20.4M	23.5M	24.7M
Other Stockholder Equity	10.3M	13.3M	28.9M	50.7M	58.3M	61.2M
Total Liab	1.0M	502.2K	593K	1.0M	1.3M	1.4M
Total Current Assets	4.4M	2.3M	10.3M	18.3M	11.0M	11.5M
Common Stock	3.4K	5.0K	25K	3K	3.5K	3.3K
Other Current Liab	323.8K	(478.3K)	(488K)	(852K)	(766.8K)	(728.5K)
Total Current Liabilities	1.0M	502.2K	526K	998K	1.3M	1.4M
Accounts Payable	348.9K	490.2K	493K	905K	1.2M	1.3M
Other Current Assets	18.6K	195.1K	252K	789K	554K	581.7K
Accumulated Other Comprehensive Income	(9.8K)	63.8K	18K	(254K)	(228.6K)	(217.2K)
Property Plant Equipment	563.0	721.0	246.0	90K	103.5K	108.7K
Non Current Assets Total	2.0M	2.0M	2.3M	2.1M	2.1M	1.5M
Non Currrent Assets Other	563.0	2.0M	189K	3K	3.5K	3.3K
Non Current Liabilities Total	529.3K	348.9K	490.2K	67K	23K	0.0
Net Invested Capital	5.5M	3.9M	12.0M	11.8M	13.5M	7.1M
Net Working Capital	3.4M	1.8M	9.8M	9.7M	11.1M	11.7M
Property Plant And Equipment Net	721.0	246.0	90K	60K	21K	31.6K
Property Plant And Equipment Gross	721.0	246.0	90K	21K	24.2K	24.5K
Capital Stock	3.4K	5.0K	25K	3K	2.7K	2.6K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Artelo Biosciences is a strong investment it is important to analyze Artelo Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Artelo Biosciences' future performance. For an informed investment choice regarding Artelo Stock, refer to the following important reports:

How To Invest In Artelo

Details

Is Artelo Stock a good investment?

Details

What is Artelo Biosciences' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.87)

Return On Assets

(0.54)

Return On Equity

(0.89)

The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Artelo Ev To Operating Cash Flow vs Roe Analysis

Ev To Operating Cash Flow vs Roe

Ev To Operating Cash Flow vs Roe Correlation Analysis

Correlation Coefficient

Ev To Operating Cash Flow

Roe

Artelo Biosciences fundamental ratios Correlations

Artelo Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Artelo Biosciences fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Net Working Capital	+ 1.0	Net Tangible Assets
Other Stockholder Equity	+ 1.0	Cash And Short Term Investments
Total Current Liabilities	+ 1.0	Total Liab

Other Stockholder Equity	- 1.0	Retained Earnings
Common Stock Shares Outstanding	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Retained Earnings
Net Debt	- 0.97	Total Assets
Short Long Term Debt Total	- 0.96	Common Stock Shares Outstanding
Accounts Payable	- 0.96	Retained Earnings